Calendar

Week of Apr 27, 2026

Apr 27, 2026phase 1 2 completion90d agoKLE Ayurveda Hospital — ayurvedic medicine (Phase I/II Trial Completion)ayurvedic medicine

Therapy area: Central Nervous System, Gastrointestinal. Indication: Anorectal Disease, Post-Operative Pain

full page →ayurvedic medicine →source: globaldata

Apr 30, 2026phase 1 2 completion87d agoBeijing Tiantan Hospital — XS-411 (Phase I/II Trial Completion)XS-411

Therapy area: Central Nervous System. Indication: Parkinson's Disease

full page →XS-411 →source: globaldata

Apr 30, 2026phase 1 2 completion87d agoAbbVie Inc — blinatumomab (Phase I/II Trial Completion)blinatumomab

Therapy area: Oncology. Indication: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

full page →blinatumomab →source: globaldata

Apr 30, 2026phase 1 2 completion87d agoBellicum Pharmaceuticals Inc — acetaminophen (Phase I/II Trial Completion)acetaminophen ER

Therapy area: Oncology. Indication: Breast Cancer, Lung Cancer, Malignant Mesothelioma, Malignant Pleural Mesothelioma, Metastatic Breast Cancer, Non-Small Cell Lung Cancer

full page →acetaminophen ER →source: globaldata

Apr 30, 2026phase 1 2 completion87d agoIRCCS Foundation National Cancer Institute — bevacizumab (Phase I/II Trial Completion)bevacizumab

Therapy area: Oncology. Indication: Metastatic Colorectal Cancer

full page →bevacizumab →source: globaldata

Apr 30, 2026phase 1 2 completion87d agoZhongshan Hospital — iNKT Cell Immunotherapy (Phase I/II Trial Completion)iNKT Cell Immunotherapy

Therapy area: Oncology. Indication: Bladder Cancer, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)

full page →iNKT Cell Immunotherapy →source: globaldata

Apr 30, 2026phase 1 2 completion87d agoNovartis AG — zigakibart (Phase I/II Trial Completion)zigakibart

Therapy area: Genito Urinary System. Indication: IgA Nephropathy (Berger's Disease)

full page →zigakibart →source: globaldata

Apr 30, 2026phase 1 2 completion87d agoAmsterdam UMC — tremelimumab (Phase I/II Trial Completion)tremelimumab

Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer

full page →tremelimumab →source: globaldata

Apr 30, 2026phase 1 2 completion87d agoInstitute of Hematology & Blood Diseases Hospital — cyclophosphamide (Phase I/II Trial Completion)cyclophosphamide

Therapy area: Oncology. Indication: B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone B-Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)

full page →cyclophosphamide →source: globaldata

Apr 30, 2026phase 1 2 completion87d agoZhejiang Doer Biologics Corp — DR-30206 (Phase I/II Trial Completion)DR-30206

Therapy area: Oncology. Indication: Adenocarcinoma Of The Gastroesophageal Junction, Colorectal Cancer, Gastrointestinal Tumor, Metastatic Colorectal Cancer

full page →DR-30206 →source: globaldata

Apr 30, 2026phase 1 2 completion87d agoUnity Health Toronto — bupivacaine (Phase I/II Trial Completion)bupivacaine

Therapy area: Musculoskeletal Disorders. Indication: Osteoarthritis

full page →bupivacaine →source: globaldata

Apr 30, 2026phase 1 2 completion87d agoHenan Provincial People's Hospital — ofatumumab (Phase I/II Trial Completion)ofatumumab

Therapy area: Central Nervous System. Indication: Neuromyelitis Optica (Devic's Syndrome)

full page →ofatumumab →source: globaldata

Apr 30, 2026phase 1 2 completion87d agoDuke University — deferiprone (Phase I/II Trial Completion)deferiprone

Therapy area: Cardiovascular, Central Nervous System. Indication: Cerebral Aneurysms, Dementia, Stroke, Subarachnoid Hemorrhage

full page →deferiprone →source: globaldata

Apr 30, 2026phase 1 2 completion87d agoUniversity Hospital Geneva — verteporfin (Phase I/II Trial Completion)verteporfin

Therapy area: Dermatology, Infectious Disease, Oncology. Indication: Melanoma, Scar, Surgical Wound Infections

full page →verteporfin →source: globaldata

Apr 30, 2026phase 1 2 completion87d agoLepu Biopharma Co Ltd — pucotenlimab (Phase I/II Trial Completion)pucotenlimab

Therapy area: Oncology. Indication: Pancreatic Cancer

full page →pucotenlimab →source: globaldata

Apr 30, 2026phase 1 2 completion87d agoJiangsu Hengrui Pharmaceuticals Co Ltd — adebrelimab (Phase I/II Trial Completion)adebrelimab

Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer

full page →adebrelimab →source: globaldata

Apr 30, 2026phase 1 2 completion87d agoMultitude therapeutics Inc — AMT-253 (Phase I/II Trial Completion)AMT-253

Therapy area: Non Malignant Disorders, Oncology. Indication: Acral Lentiginous Melanoma, Cervical Cancer, Endometrial Cancer, Gynecological Cancer, Leiomyosarcoma, Melanoma, Metastatic Melanoma, Solid Tumor, Uterine Leiomyoma (Uterine Fibroids)

full page →AMT-253 →source: globaldata

Apr 30, 2026phase 1 2 completion87d agoBayer AG — avelumab (Phase I/II Trial Completion)avelumab

Therapy area: Oncology. Indication: Bone Metastasis, Malignant Neoplasms, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Prostate Cancer

full page →avelumab →source: globaldata

Apr 30, 2026phase 1 2 completion87d agoAbbVie Inc — venetoclax (Phase I/II Trial Completion)venetoclax

Therapy area: Oncology. Indication: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Leukemia, Leukemia, T-Cell Leukemia

full page →venetoclax →source: globaldata

Apr 30, 2026phase 1 2 completion87d agoAstraZeneca Plc — Calquence (Phase I/II Trial Completion)CALQUENCE

Therapy area: Oncology. Indication: CNS Lymphoma, Diffuse Large B-Cell Lymphoma, Primary CNS Lymphoma, Secondary CNS Lymphoma

full page →CALQUENCE →source: globaldata

Apr 30, 2026phase 1 2 completion87d agoHenan Cancer Hospital — methotrexate (Phase I/II Trial Completion)Maxtrex

Therapy area: Oncology. Indication: Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis), Lung Cancer

full page →Maxtrex →source: globaldata

Apr 30, 2026phase 1 2 completion87d agoArvinas Inc — samuraciclib (Phase I/II Trial Completion)samuraciclib

Therapy area: Oncology. Indication: Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Metastatic Breast Cancer

full page →samuraciclib →source: globaldata

Apr 30, 2026phase 1 2 completion87d agoChiba Cancer Center — nivolumab (Phase I/II Trial Completion)nivolumab

Therapy area: Oncology. Indication: Adenoid Squamous Cell Carcinoma (Pseudoglandular Squamous Cell Carcinoma), Basaloid Squamous Cell Carcinoma, Esophageal Cancer, Squamous Cell Carcinoma

full page →nivolumab →source: globaldata

Apr 30, 2026phase 1 2 completion87d agoNational Cheng-Kung University Hospital — cisplatin (Phase I/II Trial Completion)cisplatin

Therapy area: Oncology. Indication: Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC)

full page →cisplatin →source: globaldata

Apr 30, 2026phase 1 2 completion87d agoImplicit Bioscience Ltd — Atibuclimab (Phase I/II Trial Completion)Atibuclimab

Therapy area: Cardiovascular. Indication: Acute Decompensated Heart Failure, Congestive Heart Failure (Heart Failure)

full page →Atibuclimab →source: globaldata

Apr 30, 2026phase 1 2 completion87d agoNakornping Hospital — bupivacaine (Phase I/II Trial Completion)bupivacaine

Therapy area: Central Nervous System. Indication: Post-Operative Pain

full page →bupivacaine →source: globaldata

Apr 30, 2026phase 1 2 completion87d agoCentre International de Développement Pharmaceutique — afamelanotide (Phase I/II Trial Completion)afamelanotide

Therapy area: Dermatology. Indication: Vitiligo

full page →afamelanotide →source: globaldata

Apr 30, 2026phase 1 2 completion87d agoEyebiotech Ltd — MK-8748 (Phase I/II Trial Completion)MK-8748

Therapy area: Ophthalmology. Indication: Age Related Macular Degeneration, Branch Retinal Vein Occlusion, Diabetic Macular Edema, Macular Edema, Wet (Neovascular / Exudative) Macular Degeneration

full page →MK-8748 →source: globaldata

Apr 30, 2026phase 1 2 completion87d agoWuhan YZY Biopharma Co Ltd — M-701 (Phase I/II Trial Completion)M-701

Therapy area: Oncology, Respiratory. Indication: Malignant Pleural Effusion, Non-Small Cell Lung Cancer

full page →M-701 →source: globaldata

Date TBD

RECRUITINGphase readoutNCT06924671: GLA:D Back Canada - a Program for Chronic and Persistent Low Back Pain

Sponsor: University of Alberta. Phase: . Conditions: Low Back Pain

full page →ctgov ↗

COMPLETEDphase readout

← prev

page 1 of 99

Week of Apr 27, 2026

Date TBD